Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lars Dyrskjøt

Showing results (1-10 of 187) with videos related to

Pageof 19
Sort By:
European Urology|September 22, 2018
Molecular Subtypes of Bladder Cancer: Academic Exercise or Clinical Relevance?Lars Dyrskjøt
Expert Review of Molecular Diagnostics|September 27, 2003
Classification of bladder cancer by microarray expression profiling: towards a general clinical use of microarrays in cancer diagnosticsLars Dyrskjøt
The New England Journal of Medicine|December 17, 2025
ctDNA-Guided Therapy in Bladder Cancer - Ready?Lars Dyrskjøt
Nature Reviews. Urology|January 17, 2019
Large-scale genomic comparison of UTUC and bladder tumoursLars Dyrskjøt
Nature Reviews. Urology|January 22, 2026
ctDNA-guided treatment decisions in muscle-invasive bladder cancerLars Dyrskjøt
Cancer Letters|December 27, 2012
The functional role of the novel biomarker karyopherin α 2 (KPNA2) in cancerAnders Christiansen, Lars Dyrskjøt
Current Opinion in Urology|August 24, 2018
Biology of nonmuscle-invasive bladder cancer: pathology, genomic implications, and immunologyLars Dyrskjøt, Molly A Ingersoll
Scandinavian Journal of Urology and Nephrology. Supplementum|December 5, 2008
Gene signatures for risk-adapted treatment of bladder cancerTorben F Ørntoft, Lars Dyrskjøt
Translational Andrology and Urology|July 10, 2024
Towards circulating tumor DNA-guided treatment of muscle-invasive bladder cancerSia Viborg Lindskrog, Lars Dyrskjøt
Current Opinion in Urology|August 15, 2006
Recent developments in molecular profiling of bladder cancerTorben F Ørntoft, Karsten Zieger, Lars Dyrskjøt
Pageof 19

Showing results (1-10 of 187) with videos related to

Sort By:
Pageof 19
European Urology|September 22, 2018
Molecular Subtypes of Bladder Cancer: Academic Exercise or Clinical Relevance?Lars Dyrskjøt
Expert Review of Molecular Diagnostics|September 27, 2003
Classification of bladder cancer by microarray expression profiling: towards a general clinical use of microarrays in cancer diagnosticsLars Dyrskjøt
The New England Journal of Medicine|December 17, 2025
ctDNA-Guided Therapy in Bladder Cancer - Ready?Lars Dyrskjøt
Nature Reviews. Urology|January 17, 2019
Large-scale genomic comparison of UTUC and bladder tumoursLars Dyrskjøt
Nature Reviews. Urology|January 22, 2026
ctDNA-guided treatment decisions in muscle-invasive bladder cancerLars Dyrskjøt
Cancer Letters|December 27, 2012
The functional role of the novel biomarker karyopherin α 2 (KPNA2) in cancerAnders Christiansen, Lars Dyrskjøt
Current Opinion in Urology|August 24, 2018
Biology of nonmuscle-invasive bladder cancer: pathology, genomic implications, and immunologyLars Dyrskjøt, Molly A Ingersoll
Scandinavian Journal of Urology and Nephrology. Supplementum|December 5, 2008
Gene signatures for risk-adapted treatment of bladder cancerTorben F Ørntoft, Lars Dyrskjøt
Translational Andrology and Urology|July 10, 2024
Towards circulating tumor DNA-guided treatment of muscle-invasive bladder cancerSia Viborg Lindskrog, Lars Dyrskjøt
Current Opinion in Urology|August 15, 2006
Recent developments in molecular profiling of bladder cancerTorben F Ørntoft, Karsten Zieger, Lars Dyrskjøt
Pageof 19